Reinwein D, Benker G, König M P, Pinchera A, Schatz H, Schleusener H
Abteilung für klinische Endokrinologie, Universität Essen.
Schweiz Med Wochenschr. 1987 Aug 22;117(34):1245-55.
Clinical aspects of 924 unselected patients with hyperthyroidism from 17 thyroid centres of 6 European countries were investigated in a prospective study for exactly 1 year. Serum samples were centrally assayed for thyroid hormones, thyroid autoantibodies and TSH-binding inhibiting immunoglobulins (TBII), and urine samples for iodine. 26 items of information per patient were computerized and evaluated. Forming 2 groups from iodine-deficient areas (IDA) and iodine-sufficient (ISA) according to the urinary iodine, it was possible to elucidate some characteristics independently of local factors. The most important findings were: 1. Three types of hyperthyroidism were described: Graves' disease was defined as hyperthyroidism with eye symptoms and/or the presence of measurable TBII; autonomous adenomas were defined by a single hot nodule in the thyroid scan; the remainder included TBII negative hyperthyroid patients as well as non-immunogenic forms of hyperthyroidism (toxic multinodular goiter and other multifocal autonomies). These were termed "non-classifiable" patients. Graves' patients, representing an average of 60% of the patients, have an age peak between 40 and 49 years; they are 10 years younger than unclassified hyperthyroid patients and 20 years younger than patients with autonomous adenoma, who represented 9.2% of the patients. Surprisingly, there was no difference in the prevalence of Graves' disease between IDA and ISA. 2. An unexpectedly high rate of 10.5% of hyperthyroid patients (Graves' disease 8.5%, non-Graves' disease 14.2%) had no goiter, a figure increasing in the elderly to almost 17%. In IDA the thyroid was larger and the goiter more often nodular than in ISA. IDA are characterized by significantly higher rates (11.3%) of autonomous adenoma than ISA (3.2%). 3. 59.4% of 507 patients with Graves' disease had eye symptoms, 44.6% of at least grade II or higher using the Werner classification. There was no difference between patients from ISA and IDA. We found unilateral ophthalmopathy in 6.7% of Graves' patients. 4. The median iodine excretion was calculated from urinary iodine after exclusion of values over 250 micrograms iodine/g creatinine, arbitrarily defined as iodine contamination. In IDA the median iodine excretion was 63.6, and in ISA 105 micrograms/g of creatinine. 5. Surprisingly, proven iodine contamination was as frequent in IDA (14.5%) as in ISA (15.2%). In the survey protocol, however, this was noticed less often by physicians in ISA.(ABSTRACT TRUNCATED AT 400 WORDS)
在一项前瞻性研究中,对来自6个欧洲国家17个甲状腺中心的924例未经挑选的甲状腺功能亢进患者进行了为期整整1年的临床研究。血清样本集中检测甲状腺激素、甲状腺自身抗体和促甲状腺激素结合抑制性免疫球蛋白(TBII),尿样检测碘含量。每位患者的26项信息进行了计算机化处理和评估。根据尿碘将患者分为碘缺乏地区(IDA)和碘充足地区(ISA)两组,从而有可能阐明一些不受当地因素影响的特征。最重要的发现如下:1. 描述了三种类型的甲状腺功能亢进:格雷夫斯病定义为伴有眼部症状和/或可检测到TBII的甲状腺功能亢进;自主性腺瘤通过甲状腺扫描中的单个热结节来定义;其余包括TBII阴性的甲状腺功能亢进患者以及非免疫原性形式的甲状腺功能亢进(毒性多结节性甲状腺肿和其他多灶性自主性病变)。这些被称为“无法分类”的患者。格雷夫斯病患者平均占患者总数的60%,年龄高峰在40至49岁之间;他们比未分类的甲状腺功能亢进患者年轻10岁,比自主性腺瘤患者年轻20岁,自主性腺瘤患者占患者总数的9.2%。令人惊讶的是,IDA和ISA之间格雷夫斯病的患病率没有差异。2. 甲状腺功能亢进患者中意外地有10.5%的比例(格雷夫斯病8.5%,非格雷夫斯病14.2%)没有甲状腺肿大,这一比例在老年人中增加到近17%。与ISA相比,IDA的甲状腺更大,甲状腺肿大更常为结节性。IDA的自主性腺瘤发生率(11.3%)明显高于ISA(3.2%)。3. 507例格雷夫斯病患者中有59.4%有眼部症状,按照维尔纳分类法,至少II级或更高等级的占44.6%。ISA和IDA的患者之间没有差异。我们发现6.7%的格雷夫斯病患者有单侧眼病。4. 在排除超过250微克碘/克肌酐的值(任意定义为碘污染)后,根据尿碘计算碘排泄中位数。在IDA中,碘排泄中位数为63.6,在ISA中为105微克/克肌酐。5. 令人惊讶的是,经证实的碘污染在IDA(14.5%)和ISA(15.2%)中同样常见。然而,在调查方案中,ISA的医生较少注意到这一点。(摘要截取自400字)